TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling

Carcinogenesis

Volumn 32, Issue 5, 2011, Pages 779-785

  Liy, Shengqing ^a   Bodey, Ann M ^a   Zhuy, Feng ^a   Liu, Kangdong ^a   Zhang, Jishuai ^a   Kim, Myoung Ok ^a   Reddy, Kanamata ^a   Zykova, Tatyana ^a   Ma, Wei Ya ^a   Carper, Andria L ^a   Langfald, Alyssa K ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; N (1,4 BENZODIOXAN 6 YL) 3 (4 TERT BUTYLPHENYL)ACRYLAMIDE; PROTEIN KINASE B; TELOMERASE; VASCULOTROPIN;

ANALGESIA; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC PAIN; CONTROLLED STUDY; DOWNSTREAM PROCESSING; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MIGRAINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK; SIGNAL TRANSDUCTION; SKIN CULTURE; SKIN TUMOR;

EID: 79955766195     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr037     Document Type: Article

References (31)

1. Nagy,I. et al. (2004) The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur. J. Pharmacol., 500, 351-369.
2. Willis,W.D.Jr. (2009) The role of TRPV1 receptors in pain evoked by noxious thermal and chemical stimuli. Exp. Brain Res., 196, 5-11.
3. Lee,Y.M. et al. (2009) Increased expression of TRPV1 channel in intrinsically aged and photoaged human skin in vivo. Exp. Dermatol., 18, 431-436.
4. Avelino,A. et al. (2006) TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch. Pharmacol., 373, 287-299.
5. Mitchell,J.E. et al. (2005) Expression and characterization of the intracellular vanilloid receptor (TRPV1) in bronchi from patients with chronic cough. Exp. Lung Res., 31, 295-306.
6. Knotkova,H. et al. (2008) Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin. J. Pain., 24, 142-154.
7. Szallasi,A. et al. (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov., 6, 357-372.
8. Gavva,N.R. et al. (2005) AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J. Pharmacol. Exp. Ther., 313, 474-484.
9. Czifra,G. et al. (2009) Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J. Cancer Res. Clin. Oncol., 135, 507-514.
10. Miao,X. et al. (2008) High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma. Cancer Genet. Cytogenet., 186, 25-32.
11. Lazzeri,M. et al. (2005) Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder. Eur. Urol., 48, 691-698.
12. Bode,A.M. et al. (2009) Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. Cancer Res., 69, 905-913.
13. Memmott,R.M. et al. (2009) Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal., 21, 656-664.
14. Papadimitrakopoulou,V. et al. (2006) The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J. Thorac. Oncol., 1, 749-751.
15. Yap,T.A. et al. (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol., 8, 393-412.
16. Carnero,A. et al. (2008) The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets, 8, 187-198.
17. Torres,J. et al. (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem., 276, 993-998.
18. Amantini,C. et al. (2009) Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis, 30, 1320-1329.
19. Amantini,C. et al. (2007) Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J. Neurochem., 102, 977-990.
20. Burgess,A.W. et al. (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell., 12, 541-552.
21. Citri,A. et al. (2006) EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol., 7, 505-516.
22. Mendelsohn,J. et al. (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol., 21, 2787-2799.
23. Normanno,N. et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366, 2-16.
24. Takeuchi,K. Ito F. (2010) EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J., 277, 316-326.
25. Morgensztern,D. et al. (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs, 16, 797-803.
26. Kim,S. et al. (2001) Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1. J. Biol. Chem., 276, 12864-12870.
27. Alessi,D.R. et al. (2009) New insights into mTOR signaling: mTORC2 and beyond. Sci. Signal., 2, pe27.
28. Sparks,C.A. Guertin (2010) DA Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene, 29, 3733-3744.
29. Bhaskar,P.T. et al. (2007) The two TORCs and Akt. Dev. Cell, 12, 487-502.
30. Cortright,D.N. et al. (2009) TRP channels and pain. Curr. Pharm. Des., 15, 1736-1749.
31. Gunthorpe,M.J. (2009) Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov. Today, 14, 56-67.